Metraipolis › archive › dc_58ef08bef6d8

Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Europe PMC PMID:42830764

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42830764
DOI
10.1016/j.ajpc.2026.101719
License (as archived)
solo-consultazione
Archived
2026-10-18T16:08:40.561Z
SHA-256 of the archived text
df6b240ee8b96b1060657cd371677049b9776e764c0c97b99408daf714d5ec69
Stable URL of this page
https://metraipolis.com/documento/dc_58ef08bef6d8

How to cite

Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Europe PMC PMID:42830764 — Europe PMC (en), https://europepmc.org/article/MED/42830764 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_58ef08bef6d8 (Metraipolis archive dc_58ef08bef6d8, sha256 df6b240ee8b96b1060657cd371677049b9776e764c0c97b99408daf714d5ec69)
BibTeX
@misc{dc58ef08bef6d8,
  title = {Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Europe PMC PMID:42830764},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42830764},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_58ef08bef6d8; sha256 df6b240ee8b96b1060657cd371677049b9776e764c0c97b99408daf714d5ec69},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42830764. Agents can read the archived copy with the MCP tool read_document.